Robotic surgery showdown: which approach saves bladder control?
NCT ID NCT06434649
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two ways of doing robotic prostate surgery in men with intermediate- to high-risk prostate cancer. One method enters from the back of the prostate, the other from the front. The goal is to see which approach better preserves urinary control and erectile function while still removing all cancer. About 118 men will take part across multiple hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- robotic surgery (posterior vs anterior approach)
- What this could lead to
- If one approach proves better, it could improve recovery of urinary control and erectile function after prostate cancer surgery.
- What could go wrong
- This is a relatively small, early-stage study (118 participants) comparing surgical techniques, not testing a new drug. Results may not apply to all patients, and individual outcomes vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
first hospital affiliated of Fujian medical university
Fuzhou, Fujian, 350005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?